Efficient Colon Cancer Immunogene Therapy Through Co-Delivery of IL-22BP mRNA and Tumor Cell Lysate by CLSV Nanoparticles

References

• Dolgin E. Cancer’s new normal. Nat Cancer. 2021;2(12):1248–1250. doi:10.1038/s43018-021-00304-7
   PubMedGoogle Scholar
• Shah SC, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology. 2022;162(3):715–730 e713. doi:10.1053/j.gastro.2021.10.035
   PubMed Web of Science ®Google Scholar
• Mullard A. Addressing cancer’s grand challenges. Nat Rev Drug Discov. 2020;19(12):825–826. doi:10.1038/d41573-020-00202-0
   PubMed Web of Science ®Google Scholar
• Wong-Rolle A, Wei HK, Zhao C, Jin C. Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein Cell. 2021;12(5):426–435. doi:10.1007/s13238-020-00813-8
   PubMed Web of Science ®Google Scholar
• Giamas G. Cancer Gene Therapy: vision and strategy for the new decade. Cancer Gene Ther. 2020;27(3–4):115. doi:10.1038/s41417-020-0169-8
   PubMed Web of Science ®Google Scholar
• Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. mRNA-based cancer therapeutics. Nat Rev Cancer. 2023;23(8):526–543. doi:10.1038/s41568-023-00586-2
   PubMed Web of Science ®Google Scholar
• Fabbri L, Chakraborty A, Robert C, Vagner S. The plasticity of mRNA translation during cancer progression and therapy resistance. Nat Rev Cancer. 2021;21(9):558–577. doi:10.1038/s41568-021-00380-y
   PubMed Web of Science ®Google Scholar
• Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303–322. doi:10.1038/s41568-020-0253-2
   PubMed Web of Science ®Google Scholar
• Papachristofilou A, Hipp MM, Klinkhardt U, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2019;7(1):38. doi:10.1186/s40425-019-0520-5
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2020;586(7830):594–599. doi:10.1038/s41586-020-2814-7
   PubMed Web of Science ®Google Scholar
• Chablani L, Singh V. Cell-penetrating peptides as passive permeation enhancers for transdermal drug delivery. AAPS Pharm Sci Tech. 2022;23(7):266. doi:10.1208/s12249-022-02424-4
   PubMed Web of Science ®Google Scholar
• Khan MM, Filipczak N, Torchilin VP. Cell penetrating peptides: a versatile vector for co-delivery of drug and genes in cancer. J Control Release. 2021;330:1220–1228. doi:10.1016/j.jconrel.2020.11.028
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298–312. doi:10.1038/s41568-021-00339-z
   PubMed Web of Science ®Google Scholar
• Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215–229. doi:10.1038/s41571-020-00460-2
   PubMed Web of Science ®Google Scholar
• van den Bulk J, Verdegaal EM, de Miranda NF. Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol. 2018;8(6). doi:10.1098/rsob.180037
   PubMed Web of Science ®Google Scholar
• He J, Xiong X, Yang H, et al. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Res. 2022;32(6):530–542. doi:10.1038/s41422-022-00627-9
   PubMed Web of Science ®Google Scholar
• Olivier T, Migliorini D. Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: what happened to the evidence? Rev Neurol. 2023;179(5):502–505. doi:10.1016/j.neurol.2023.03.014
   PubMedGoogle Scholar
• Gao Y, Men K, Pan C, et al. Functionalized DMP-039 hybrid nanoparticle as a novel mRNA vector for efficient cancer suicide gene therapy. Int J Nanomed. 2021;16:5211–5232. doi:10.2147/IJN.S319092
   PubMed Web of Science ®Google Scholar
• Li J, Men K, Gao Y, et al. Single micelle vectors based on lipid/block copolymer compositions as mRNA formulations for efficient cancer immunogene therapy. Mol Pharm. 2021;18(11):4029–4045. doi:10.1021/acs.molpharmaceut.1c00461
   PubMed Web of Science ®Google Scholar
• Lim C, Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev. 2014;25(3):257–271. doi:10.1016/j.cytogfr.2014.04.005
   PubMed Web of Science ®Google Scholar
• Markota A, Endres S, Kobold S. Targeting interleukin-22 for cancer therapy. Hum Vaccin Immunother. 2018;14(8):2012–2015. doi:10.1080/21645515.2018.1461300
   PubMed Web of Science ®Google Scholar
• Lei S, Zhang X, Men K, et al. Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation. Mol Pharm. 2020;17(9):3378–3391. doi:10.1021/acs.molpharmaceut.0c00451
   PubMedGoogle Scholar
• Zhang X, Cai A, Gao Y, Zhang Y, Duan X, Men K. Treatment of melanoma by nano-conjugate-delivered Wee1 siRNA. Mol Pharm. 2021;18(9):3387–3400. doi:10.1021/acs.molpharmaceut.1c00316
   PubMedGoogle Scholar
• Macri C, Pang ES, Patton T, O’Keeffe M. Dendritic cell subsets. Semin Cell Dev Biol. 2018;84:11–21. doi:10.1016/j.semcdb.2017.12.009
   PubMed Web of Science ®Google Scholar
• Sadeghzadeh M, Bornehdeli S, Mohahammadrezakhani H, et al. Dendritic cell therapy in cancer treatment; the state-of-The-art. Life Sci. 2020;254:117580. doi:10.1016/j.lfs.2020.117580
   PubMed Web of Science ®Google Scholar
• Oberli MA, Reichmuth AM, Dorkin JR, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017;17(3):1326–1335. doi:10.1021/acs.nanolett.6b03329
   PubMed Web of Science ®Google Scholar
• Mai Y, Guo J, Zhao Y, Ma S, Hou Y, Yang J. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cell Immunol. 2020;354:104143. doi:10.1016/j.cellimm.2020.104143
   PubMed Web of Science ®Google Scholar
• Capasso Palmiero U, Kaczmarek JC, Fenton OS, Anderson DG. Poly(beta-amino ester)-co-poly(caprolactone) Terpolymers as nonviral vectors for mRNA delivery in vitro and in vivo. Adv Healthc Mater. 2018;7(14):e1800249. doi:10.1002/adhm.201800249
   PubMed Web of Science ®Google Scholar
• Miao L, Li L, Huang Y, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37(10):1174–1185. doi:10.1038/s41587-019-0247-3
   PubMed Web of Science ®Google Scholar
• Rapoport M, Saada A, Elpeleg O, Lorberboum-Galski H. TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency. Mol Ther. 2008;16(4):691–697. doi:10.1038/mt.2008.4
   PubMed Web of Science ®Google Scholar
• Saifi MA, Sathish G, Bazaz MR, Godugu C. Exploration of tumor penetrating peptide iRGD as a potential strategy to enhance tumor penetration of cancer nanotherapeutics. Biochim Biophys Acta Rev Cancer. 2023;1878(3):188895. doi:10.1016/j.bbcan.2023.188895
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–221. doi:10.1038/nature22991
   PubMed Web of Science ®Google Scholar
• Andrejeva G, Rathmell JC. Similarities and distinctions of cancer and immune metabolism in inflammation and tumors. Cell Metab. 2017;26(1):49–70. doi:10.1016/j.cmet.2017.06.004
   PubMed Web of Science ®Google Scholar
• Mendiratta SK, Quezada A, Matar M, et al. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. Gene Ther. 1999;6(5):833–839. doi:10.1038/sj.gt.3300891
   PubMed Web of Science ®Google Scholar
• Denda-Nagai K, Kubota N, Tsuiji M, Kamata M, Irimura T. Macrophage C-type lectin on bone marrow-derived immature dendritic cells is involved in the internalization of glycosylated antigens. Glycobiology. 2002;12(7):443–450. doi:10.1093/glycob/cwf061
   PubMed Web of Science ®Google Scholar
• Wang X, Wang N, Yang Y, et al. Polydopamine nanoparticles carrying tumor cell lysate as a potential vaccine for colorectal cancer immunotherapy. Biomater Sci. 2019;7(7):3062–3075. doi:10.1039/c9bm00010k
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022. doi:10.3389/fimmu.2019.02022
   PubMed Web of Science ®Google Scholar
• Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer. 2021;12(9):2735–2746. doi:10.7150/jca.57334
   PubMed Web of Science ®Google Scholar